Insmed
Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company's value proposition centers on its proprietary drug delivery technologies, such as Pulmovance liposomal delivery, and its ability to advance first-in-class treatments for chronic lung infections and inflammatory conditions.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Respiratory
primaryThe company's primary therapeutic area focused on chronic and rare pulmonary conditions, including nontuberculous mycobacterial (NTM) lung disease and bronchiectasis. This segment includes the company's two commercial products and several advanced clinical-stage candidates.
ARIKAYCE, BRINSUPRI, TPIP, INS1148
Specialty pharmacies, Hospitals, Healthcare providers, Patients with rare lung diseases
Immunology & Inflammation
moderateFocuses on small molecule inhibitors targeting inflammatory pathways, specifically dipeptidyl peptidase 1 (DPP1) for systemic inflammatory diseases. The lead program is currently evaluating treatments for hidradenitis suppurativa.
brensocatib
Dermatologists, Clinical trial participants
Neuro & Other Rare
minorDedicated to developing intrathecally delivered gene therapies for rare neuromuscular and neurological disorders. These programs utilize adeno-associated virus (AAV) technology to target genetic drivers of disease.
INS1201, INS1202
Neurologists, Clinical trial participants
Segment Financials
TPIP external R&D expenses — R&D
View metricINS1148 — R&D
View metricARIKAYCE external R&D expenses — R&D
View metricBrensocatib external R&D expenses — R&D
View metricOther external R&D expenses — R&D
View metricBusiness Overview
Competitive Position
Insmed holds a leading position in the NTM lung disease market with the only approved inhaled therapy in major regions and is a first-mover in the bronchiectasis space with the recent approval of BRINSUPRI.
Geographies
United States, European Union, Japan, United Kingdom
Customer Segments
Specialty healthcare providers, Rare disease patients, National health systems
Upstream Dependencies
Contract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Specialized medical device manufacturers, Clinical Research Organizations (CROs)
Downstream Customers
Specialty pharmacies, Full-line pharmaceutical wholesalers, Hospitals and clinics, Governmental health reimbursement agencies
Competitors & Partners
Competitors
Partners
AstraZeneca
AZN
Licensing partner for brensocatib (BRINSUPRI)
PARI Pharma GmbH
Manufacturer and developer of the Lamira nebulizer device used for ARIKAYCE
Thermo Fisher Scientific
TMO
Parent company of manufacturing and clinical service partners Patheon and PPD
Resilience Biotechnologies Inc.
Contract manufacturer for ARIKAYCE
Esteve Química, S.A.
Commercial manufacturing partner for brensocatib API
Opsidio LLC
Original developer of INS1148 from whom rights were acquired
United Therapeutics
UTHR
Competitor in the treprostinil and pulmonary hypertension market
Insmed FAQ
Common questions about Insmed
Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company's value proposition centers on its proprietary drug delivery technologies, such as Pulmovance liposomal delivery, and its ability to advance first-in-class treatments for chronic lung infections and inflammatory conditions.
Insmed (INSM) has a market capitalization of $23.2B and trades on NASDAQ.
Insmed generated $819.6M in trailing twelve-month revenue with a net loss of $1.2B, representing a net margin of -144.4%. Gross margin stands at 81.8%, with free cash flow of -$921.6M. These figures are based on the Q1 2026 filing.
Insmed's key competitors include United Therapeutics Corporation, Sarepta Therapeutics, Inc., Amgen Inc, and others. These companies compete in similar markets and product categories.
Insmed has approximately 912 employees.